Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020 - PRNewswire

Submitted by Anonymous (not verified) on Fri, 08/28/2020 - 15:31

Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020 PRNewswire

Log in to post comments